Condition

Relapsed/Refractory B-cell Lymphoma clinical trials and research

As of November 12, 2026, Find a Trial lists 3 Relapsed/Refractory B-cell Lymphoma clinical trials that are recruiting, in China. By phase: Phase 1/2 (2), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.

Newest Relapsed/Refractory B-cell Lymphoma clinical trials

StudyPhaseWhereStatusRegistered
CD19/CD20 CAR/TRuC-T for relapsed or refractory B‑cell lymphoma Phase 1/2 Shenzhen, Guangdong Recruiting Apr 2, 2026
Autocrine p40 CD19/CD20 dual-targeting CAR-T therapy for relapsed or refractory B-cell lymphoma Phase 1/2 Shenzhen, Other (Non U.s.) Recruiting Jul 31, 2025
Evaluating ISM8207 for advanced solid tumors and B-cell lymphoma Phase 1 Beijing, Beijing Municipality and 3 other locations Recruiting Jun 6, 2024

All recruiting trials (3)

Related topics

Advanced Solid TumorsChimeric antigen receptor

Quick answers

How many Relapsed/Refractory B-cell Lymphoma clinical trials are recruiting right now?

3, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 2, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →

Last reviewed 2026-11-12 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.